Related Experiment Videos
Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies
Oliver A Cornely1, Andrew J Ullmann, Meinolf Karthaus
1Klinik I für Innere Medizin, Klinikum der Universität Köln, Cologne, Germany.
Abstract:
Invasive fungal infection is an increasing source of morbidity and mortality in patients with hematologic malignancies, particularly those with prolonged and severe neutropenia (absolute white blood cell count < 100/microL). Early diagnosis of invasive fungal infection is difficult, suggesting that antifungal prophylaxis could be the best approach for neutropenic patients undergoing intensive myelosuppressive chemotherapy. Consequently, antifungal prophylaxis has been extensively studied for more than 20 years. Nonabsorbable polyenes reduce superficial mycoses but are not effective in preventing or treating invasive fungal infections. Intravenous amphotericin B and the newer azoles were used in numerous clinical trials, but the value of antifungal prophylaxis in defined risk groups with cancer is still open to discussion. Recipients of allogeneic stem cell transplants and patients with a relapsed leukemia are high-risk patient populations. In addition, certain risk factors are well defined, for example, neutropenia more than 10 days, corticosteroid therapy, sustained immunosuppression, and graft-versus-host disease. In contrast to study efforts, evidence-based recommendations on the clinical use of antifungal prophylaxis according to risk groups are rare. The objective of this review of 50 studies accumulating more than 9000 patients is to assess evidence-based criteria with regard to the efficacy of antifungal prophylaxis in neutropenic cancer patients.
Insights
Antifungal prophylaxis is crucial for neutropenic cancer patients due to high infection risks. This review assesses evidence for its efficacy in preventing invasive fungal infections in these vulnerable populations.
Area of Science:
- Oncology
- Infectious Diseases
- Hematology
Background:
- Invasive fungal infections (IFIs) significantly increase morbidity and mortality in hematologic malignancy patients, especially those with prolonged neutropenia.
- Early diagnosis of IFIs is challenging, making antifungal prophylaxis a critical strategy for neutropenic patients undergoing intensive chemotherapy.
- Despite extensive research, evidence-based guidelines for antifungal prophylaxis in specific cancer patient risk groups remain limited.
Purpose of the Study:
- To review 50 studies involving over 9000 patients to establish evidence-based criteria for antifungal prophylaxis efficacy.
- To assess the effectiveness of antifungal prophylaxis in neutropenic cancer patients.
- To provide clarity on the clinical use of antifungal prophylaxis based on defined risk groups.
Main Methods:
- Systematic review of 50 clinical studies.
- Analysis of data from over 9000 neutropenic cancer patients.
- Evaluation of antifungal prophylaxis efficacy in various risk strata.
Main Results:
- Nonabsorbable polyenes are ineffective for invasive fungal infections.
- Intravenous amphotericin B and azoles have been evaluated in numerous trials, but their prophylactic value is debated.
- High-risk populations include allogeneic stem cell transplant recipients and relapsed leukemia patients, with factors like prolonged neutropenia and corticosteroid use increasing risk.
Conclusions:
- Antifungal prophylaxis is a key consideration for neutropenic cancer patients at high risk for invasive fungal infections.
- Further evidence-based recommendations are needed to guide the clinical application of antifungal prophylaxis in defined risk groups.
- The review aims to consolidate existing data to support informed decision-making regarding antifungal prophylaxis strategies.